Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man.

Feinberg I, Jones R, Walker JM, Cavness C, March J.

Clin Pharmacol Ther. 1975 Apr;17(4):458-66.

PMID:
164314
2.

Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria.

Jia W, Hegde VL, Singh NP, Sisco D, Grant S, Nagarkatti M, Nagarkatti PS.

Mol Cancer Res. 2006 Aug;4(8):549-62.

3.

Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH.

Biol Psychiatry. 2005 Mar 15;57(6):594-608.

PMID:
15780846
4.

Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol.

Cone EJ, Johnson RE, Darwin WD, Yousefnejad D, Mell LD, Paul BD, Mitchell J.

J Anal Toxicol. 1987 May-Jun;11(3):89-96.

PMID:
3037193
5.

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, Pakdel A, Allison J, Limbad C, Moore DH, Yount GL, Desprez PY, McAllister SD.

Mol Cancer Ther. 2010 Jan;9(1):180-9. doi: 10.1158/1535-7163.MCT-09-0407. Epub 2010 Jan 6.

6.

Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol.

Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R.

J Pharm Sci. 2006 Jun;95(6):1308-17.

PMID:
16637053
7.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK.

Curr Pharm Des. 2012;18(32):4966-79. Review.

PMID:
22716148
8.

Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways.

Behan AT, Hryniewiecka M, O'Tuathaigh CM, Kinsella A, Cannon M, Karayiorgou M, Gogos JA, Waddington JL, Cotter DR.

Neuropsychopharmacology. 2012 Jun;37(7):1773-83. doi: 10.1038/npp.2012.24. Epub 2012 Mar 21.

9.

Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z, Zuardi AW, McGuire PK.

Arch Gen Psychiatry. 2009 Jan;66(1):95-105. doi: 10.1001/archgenpsychiatry.2008.519.

PMID:
19124693
10.

A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.

Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L.

Br J Cancer. 2006 Jul 17;95(2):197-203. Epub 2006 Jun 27.

11.

Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.

Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli P, Rubia K, Kambeitz J, O'Carroll C, Seal ML, Giampietro V, Brammer M, Zuardi AW, Atakan Z, McGuire PK.

Arch Gen Psychiatry. 2012 Jan;69(1):27-36. doi: 10.1001/archgenpsychiatry.2011.161.

PMID:
22213786
12.
13.
14.

Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop.

Röhrich J, Schimmel I, Zörntlein S, Becker J, Drobnik S, Kaufmann T, Kuntz V, Urban R.

J Anal Toxicol. 2010 May;34(4):196-203.

16.

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

Carroll CB, Zeissler ML, Hanemann CO, Zajicek JP.

Neuropathol Appl Neurobiol. 2012 Oct;38(6):535-47. doi: 10.1111/j.1365-2990.2011.01248.x.

PMID:
22236282
17.

Effects of δ9-tetrahydrocannabinol on human working memory function.

Bossong MG, Jansma JM, van Hell HH, Jager G, Oudman E, Saliasi E, Kahn RS, Ramsey NF.

Biol Psychiatry. 2012 Apr 15;71(8):693-9. doi: 10.1016/j.biopsych.2012.01.008. Epub 2012 Feb 17.

PMID:
22341370
18.

Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice.

Spiro AS, Wong A, Boucher AA, Arnold JC.

PLoS One. 2012;7(4):e35937. doi: 10.1371/journal.pone.0035937. Epub 2012 Apr 20.

19.

Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum.

Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JM, Ramsey NF, Lammertsma AA, Kahn RS.

Neuropsychopharmacology. 2009 Feb;34(3):759-66. doi: 10.1038/npp.2008.138. Epub 2008 Aug 27.

20.

Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.

Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM.

Br J Clin Pharmacol. 2012 Jul;74(1):42-53. doi: 10.1111/j.1365-2125.2012.04164.x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk